JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab in HNSCC With Residual Disease After Radiation
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab In Central Nervous System Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
- Status
- COMPLETED
- Phase
- PHASE2
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2